PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885

INSTRUCTIONS: This for appropriate, All further cu indicated unless corrected maintenance fee notificatio	rm should be used for transcrespondence including the below or directed otherwisens.	mitting the ISSU ntent. advance on in Block 1, by (a	E FEE and PUBLIC dors and notification) specifying a new o	CATION FEE (if requi of maintenance fees w orrespondence address;	red). Blocks 1 through 5 : all be mailed to the current and/or (b) indicating a sep	should be completed where t correspondence address as arate "FEE ADDRESS" for	
CURRENT CORRESPONDENCE ADDRESS (None: Uso Block 1 for any change of address)				Note: A certificate of mailing can only be used for domestic mailings of the Fcc(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.			
23914 7:	590 02/16/2006		Cor	Silente of Malling or Tran	· smission		
LOUIS J. WILLE BRISTOL-MYERS SQUIBB COMPANY PATENT DEPARTMENT				I hereby certify that this Fec(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addrassed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.			
P O BOX 4000				Debra A.	Wojcik	(Depositor's name)	
PRINCETON, NJ 08543-4000				Dalfra (I Werell	(Signature)	
				March 21	2006 ∬	(Date)	
APPLICATION NO,	FILING DATE		fursicnamed induen	TOR	VIIOSMAN DOCKEL NO	CONFIRMATION NO.	
10/67E,331	DU 7464 NP 2556						
TITLE OF INVENTION: TRIAZOLONE AND TRIAZOLETHIONE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR INF-ALPHA CONVERTING ENZYME							
APPLN. TYPE	SMALL ENTITY	ISSUE P	EE PI	UBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE	
nonprovisional	NO	\$1400)	\$300	\$1700	. 05/16/2006	
EXAMINER		ART UNIT		LASS-SUBCLASS	j		
Lambkin, deborah C		1626		514-340000	· <u>·</u>		
I. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) smached. 3 "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.			2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively. (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.				
3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)							
PLBASE NOTE: Unless an assignce is identified below, no assignee data will appear on the patent. If an assignce is identified below, the document has been filed for recordation as act forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. 103/21/2006 HDEMESS2 00000031 193880 (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) Bristol-Myers Squibb Company Princeton, NJ 08543 01 FC:1501 1400.00 DA Reel/Frame: 014255/0682 02 FC:1504 300.00 DA Reel/Frame: 014255/0682 03 FC:8001 30.00 DA Please check the appropriate assignee category or campories (will not be printed on the patent):							
-40. The following focts fine enclosed: A check in the amount of the fee(s) is enclosed.							
133111 1 100				lit card. Form PTO-203			
The Market Was Comies 10				Director is hereby authorized by charge the required fee(s), or credit any overpayment, to osit Account Number 19-3880 (enclose an extra copy of this form).			
5. Change in Entity Status (from status indicated above) \[\begin{align*} \text{ a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.} \] \[\begin{align*} \text{ b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).} \]							
The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above, NOTE: The Issue Pee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.							
Authorized Signature				Date	March o	1-1, 2006	
Typed or printed name Time & Sum Registration No							
This collection of informa	tion is required by 37 CFR 1 ality is governed by 35 U.S.C	11. The informati 122 and 37 CFR	on is required to obta 1.14. This collection	in or retain a benefit by is estimated to take 12	the public which is to file (a minutes to complete, included the complete of the amount of	ing guthering, preparing, and	


an approximate commentation of the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450. Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

BEST AVAILABLE COPY

10678331





Bristol-Myers Squibb Company Patent Department

DATE: March 21, 2006

FACSIMILE TRANSMITTAL SHEET

URGENT

TO:

USPTO - Issue Fee Branch

FAX NO.:

(571) 273-2885

FROM:

Jing G. Sun, Ph.D.

TELEPHONE NO.:

(609) 252-3791

FACSIMILE NO.:

(609) 252-4526

RE:

U.S. Application Serial No.: 10/678,331 Attorney Docket No.: PH7464 NP

Number of Pages:

3 (including cover sheet)

CERTIFICATE OF TRANSMISSION VIA FACSIMILE

I hereby certify that this correspondence, a 1) Issue Fee Transmittal (1 page); and 2) "Fee Address" Indication Form (1 page) are being facsimile transmitted to the U.S. Patent and Trademark Office, Fax number (571) 273-2885, on March 21, 2006.

Woicik/Depositor

THE INFORMATION CONTAINED IN THIS FAX MESSAGE IS INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE RECIPIENT(S) NAMED ABOVE. THIS MESSAGE MAY BE AN ATTORNEY-CLIENT COMMUNICATION AND AS SUCH IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR AN AGENT RESPONSIBLE FOR DELIVERING TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR AND THAT ANY REVIEW, DISSEMINTATION, DISTRIBUTION, OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YO HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.